Continue Learning About Allergy Immunotherapy

Allergy Immunotherapy Primer

An introduction to allergy immunotherapy (AIT). This brochure covers efficacy, safety, and tips for discussing subcutaneous and sublingual AIT with patients.


Patient Allergy Immunotherapy Primer

Give patients the opportunity to learn more about allergy immunotherapy, and what to expect when being treated with immunotherapy.


Skintestor OMNITM Brochure

A deep dive on the benefits and features of our multiple-site testing device.


Stallergenes Greer Allergy Products and Services Catalog

Covers the specifics of all the allergy products and services offered by Stallergenes Greer.


Stallergenes Greer Portfolio Brochure

Learn about the Stallergenes Greer products and services that can help you administer AIT in your office.


Stallergenes Greer also offers a sublingual grass allergy immunotherapy tablet treatment option. Learn more.

Sign up for the Skin Testing Proficiency Program, and participate in either a live or online training session.

Back to top


Allergenic extracts are indicated for skin test diagnosis and treatment (immunotherapy) of patients with seasonal and perennial allergies.

See the package inserts for the full Prescribing Information for the specific extracts.


  • Do not inject intravenously.
  • Do not administer these products to patients with severe, unstable, or uncontrolled asthma.
  • Allergenic extracts may cause severe life-threatening systemic reactions, including the rare occurrence of anaphylaxis or death. Systemic reactions include: generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, and hypotension. Other adverse reactions include: nausea, emesis, abdominal cramps, and diarrhea.
  • Intended for use only by physicians who are experienced in the administration of allergenic extracts.
  • Observe patients in the office for at least 30 minutes following treatment. Emergency measures and personnel trained in their use must be available immediately in the event of a life-threatening reaction.
  • Patients with extreme sensitivity to these products, those on an accelerated immunotherapy build-up schedule, those switching to another allergenic lot, those receiving high doses of these products, or those also exposed to similar allergens may be at increased risk of a severe allergic reaction.
  • Immunotherapy may not be suitable for patients with medical conditions that reduce their ability to survive a severe allergic reaction.
  • These products may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

Please click here for Package Inserts with full Prescribing Information, including Boxed Warnings.

To report suspected adverse reactions, contact Stallergenes Greer at 1-855-274-1322 or FDA at 1-800-FDA-1088 or